Profile
Sector:
HealthcareCountry:
IndiaIPO:
11 April 2001Website:
http://www.drreddys.comNext earnings report:
26 July 2024Last dividends:
07 July 2023Next dividends:
30 July 2024Price
after hours | Wed, 03 Jul 2024 20:36:21 GMTAnalysts recommendations
Institutional Ownership
RDY Latest News
Dr. Reddy's (RDY) is set to acquire Haleon's leading global NRT brand, Nicotinell, and its related portfolio across all formats of the drug for GBP 500 million to boost its OTC presence worldwide.
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #CEO--Dr. Reddy's Laboratories Ltd. today announced the appointment of Milan Kalawadia as Chief Executive Officer, North America.
Dr. Reddy's (RDY) announces entering into a license and supply agreement with Alvotech to develop and commercialize the latter's biosimilar candidate, AVT03, to Prolia and Xgeva.
The Zacks Medical - Generic Drugs industry is starting to see some relief from macroeconomic challenges, with new product releases benefiting companies like RDY, TEVA, and VTRS.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Dr. Reddy's (RDY) reports better-than-expected fiscal third-quarter 2024 results where both earnings and revenues beat estimates, driven by growth in core businesses in North America and Europe.
- 1(current)
What type of business is Dr Reddys Laboratories Limited?
Dr. Reddy's Laboratories Limited is a global pharmaceutical company founded in 1984, headquartered in Hyderabad, India. The main activities of the company include manufacturing generic and patented drugs for use in various medical fields such as neurology, dermatology, gastroenterology, and oncology. The product portfolio also includes pain relievers and vaccines. In Russia, the following pharmaceutical brands are known: Nise, Omez, Nazivin, Ibuklin. Another business direction of Dr. Reddy's is the production and sale of active pharmaceutical ingredients and their intermediates (API), used in the manufacture of medicinal products.
What sector is Dr Reddys Laboratories Limited in?
Dr Reddys Laboratories Limited is in the Healthcare sector
What industry is Dr Reddys Laboratories Limited in?
Dr Reddys Laboratories Limited is in the Drug Manufacturers - Specialty & Generic industry
What country is Dr Reddys Laboratories Limited from?
Dr Reddys Laboratories Limited is headquartered in India
When did Dr Reddys Laboratories Limited go public?
Dr Reddys Laboratories Limited initial public offering (IPO) was on 11 April 2001
What is Dr Reddys Laboratories Limited website?
https://www.drreddys.com
Is Dr Reddys Laboratories Limited in the S&P 500?
No, Dr Reddys Laboratories Limited is not included in the S&P 500 index
Is Dr Reddys Laboratories Limited in the NASDAQ 100?
No, Dr Reddys Laboratories Limited is not included in the NASDAQ 100 index
Is Dr Reddys Laboratories Limited in the Dow Jones?
No, Dr Reddys Laboratories Limited is not included in the Dow Jones index
When does Dr Reddys Laboratories Limited report earnings?
The next expected earnings date for Dr Reddys Laboratories Limited is 26 July 2024